Clinical trial · Observational
The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC）
Comparison of the Prognosis and Safety of Different Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: A National Multicenter Real-World Study(NEO-EC）
NCT06828718CI-TRIAL-00086024NEO-ECactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The prognosis and safety of patients with locally advanced esophageal squamous cell carcinoma were compared with different neoadjuvant therapy modes in multi-cancer centers in China
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Carcinoma | Esophageal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (4)
- label
- Neoadjuvant chemoradiotherapy
- description
- Patients with locally advanced esophageal squamous cell carcinoma received neoadjuvant chemoradiotherapy and then underwent surgical resection
- label
- Neoadjuvant chemotherapy
- description
- Patients with locally advanced esophageal squamous cell carcinoma received neoadjuvant chemotherapy followed by surgical resection
- label
- Neoadjuvant chemotherapy combined with immunotherapy
- description
- Patients with locally advanced esophageal squamous cell carcinoma underwent surgical resection after neoadjuvant chemotherapy combined with immunotherapy
- label
- Neoadjuvant chemoradiotherapy combined with immunotherapy
- description
- Patients with locally advanced esophageal squamous cell carcinoma underwent surgical resection after neoadjuvant chemoradiotherapy combined with immunotherapy
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 years, male or female; 2. KPS score (KPS) ≥70; 3. Esophageal squamous cell carcinoma confirmed by histopathology; 4. Clinical stage cT1b-4aN+M0,T3-4aN0M0; 5. Surgical resection was performed after 2\~4 cycles of neoadjuvant therapy. 6. Expected survival \> 6 months. Exclusion Criteria: 1. Have a history of other malignancies (except for cancer in situ that has been cured and other malignancies that have been cured for more than 5 years); 2. There are contraindications of immunotherapy or chemoradiotherapy; 3. Inability to tolerate or refuse surgery; 4. Distant metastasis has occurred;
References
Publications (1)
- DERIVEDYan K, Wu Z, Liu X, Liu Y, Qian P, Gao M, Wang X, Guo X, Shen W. Safety and Survival Outcomes of Neoadjuvant Chemoradiotherapy Combined with Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Analysis (NEO-EC-01). Ann Surg Oncol. 2026 Jun;33(6):5387-5398. doi: 10.1245/s10434-026-19196-x. Epub 2026 Feb 28. PMID 41764126